Cargando…
Emergence of lung cancer with a low PD-L1 expression level after the administration of immune check point inhibitor for lung adenocarcinoma with a high PD-L1 expression level: A case report
BACKGROUND: Checkpoint therapy against PD-1 has proven effective and positive results have been observed in several types of cancer, including lung cancer, renal cancer, lymphoma and melanoma. However, the effects of long-term ICI treatment remain insufficient and the development of resistance is an...
Autores principales: | Iwai, Shun, Funasaki, Aika, Sekimura, Atsushi, Motono, Nozomu, Usuda, Katsuo, Yamada, Sohsuke, Ueda, Yoshimichi, Akasaki, Kyouta, Tanimura, Kouta, Kase, Kazumasa, Uramoto, Hidetaka |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320235/ https://www.ncbi.nlm.nih.gov/pubmed/32612822 http://dx.doi.org/10.1016/j.amsu.2020.05.021 |
Ejemplares similares
-
Higher Tumor Mutation Burden and Higher PD-L1 Activity Predicts the Efficacy of Immune Checkpoint Inhibitor Treatment in a Patient With Four Lung Cancers. A Case Report
por: Usuda, Katsuo, et al.
Publicado: (2020) -
Diffusion-weighted magnetic resonance imaging is useful for the response evaluation of chemotherapy and/or radiotherapy to recurrent lesions of lung cancer
por: Usuda, Katsuo, et al.
Publicado: (2019) -
Lung cancer combined with methotrexate-associated lymphoproliferative disorder: A case report
por: Sekimura, Atsushi, et al.
Publicado: (2019) -
FDG-PET/CT and diffusion-weighted imaging for resected lung cancer: correlation of maximum standardized uptake value and apparent diffusion coefficient value with prognostic factors
por: Usuda, Katsuo, et al.
Publicado: (2018) -
Diffusion-Weighted Imaging Can Differentiate between Malignant and Benign Pleural Diseases
por: Usuda, Katsuo, et al.
Publicado: (2019)